All In Biotech

Free tool

FAERS Monitor: Corlanor

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206143 or its brand name (Corlanor, Ivabradine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

6,950

Serious

5,003

72% of reports

Hospitalization

2,513

Death reported

532

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use1,369
  • dyspnoea478
  • hypotension450
  • dizziness366
  • cardiac failure347
  • fatigue342
  • drug interaction332
  • drug ineffective302
  • nausea276
  • bradycardia258
  • headache251
  • chest pain206
  • malaise194
  • palpitations182
  • oedema peripheral170

Reports by year received

View as table
YearReports
20071
20085
20096
201011
201121
201242
201355
2014105
2015336
2016683
2017603
2018582
2019546
2020610
2021574
2022663
2023529
2024575
2025610
2026393

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,209 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bradycardiaSignal25814.813.13,297
cardiac failureSignal34713.111.93,876
hypotensionSignal4506.86.22,238
drug interactionSignal3326.35.71,498
off label useSignal1,3694.74.54,201
palpitationsSignal1824.74.1530
oedema peripheralSignal1704.23.6417
chest painSignal2063.42.9343
dyspnoeaSignal4782.62.3464
dizzinessSignal3662.22.0250
malaise1941.31.217
fatigue3421.31.229
headache2511.21.19
nausea2761.10.91
drug ineffective3020.70.643

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.